WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

M MUSCULO-SKELETAL SYSTEM
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM

This group comprises preparations used in disorders of the musculo-skeletal system, which cannot be classified in the preceding groups.


M09AA Quinine and derivatives

Hydroquinine, which is used in the treatment of nocturnal leg cramps is classified in this group.
Quinine is classified as an antimalaria agent in P01BC. Quinine in combination with psycholeptics is classified in M09AA72, since these combinations are used for treatment of nocturnal leg cramps.
Combinations used for cold conditions, containing quinine as an antipyretic, are classified in R05X.

M09AB Enzymes

All enzyme preparations, which are used to treat inflammatory conditions in the musculo-skeletal system, are classified in this group.

M09AX Other drugs for disorders of the musculo-skeletal system

Hyaluronic acid injection for intraarticular administration (e.g. 2.5 mg/ampoule) used in the treatment of arthritis is classified in this group. Hyaluronic acid injection used during surgical procedures on the eye (e.g. 4-20 mg/ampoule) is classified in S01K.
Mexiletine indicated for myotonic disorders is classified in C01BB.

The DDD for hyaluronic acid is based on intraarticular treatment of arthritis. The DDD is assigned according to daily dose even if the product is given as weekly injections.

Last updated: 2024-01-26